V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Tech — Hardware

Azenta Executive Compensation (FY25)

AZTA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
John Marotta
Median of the other named officers
$1,986,245
6 officers, excluding the chief executive
Latest say-on-pay support
=
January 28, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Tech — Hardware, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Azenta brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (EX-10): April 7, 2026
17 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Azenta brief$1,500Get the executive brief
Velarion Member, one year
345 figures on this page: 334 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Marotta: $638,811 → $10,371,414
Say-on-pay support: 99.4% → 96.3% (3.1 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Azenta's chief executive and what were they paid?
John Marotta was paid $10,371,414 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $638,811 reported for fiscal 2024, Marotta's total was up.
What was Azenta's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.3% of votes cast for or against in favor at the meeting held January 28, 2026.
Which companies are in Azenta's peer group?
The disclosed peer group names 10x Genomics, Inc., Bio-Techne Corporation, Certara, Inc., Cryoport, Inc. and Cytek Biosciences, Inc., among others. Companies named in the Azenta Compensation Peer Group include 10x Genomics, Inc., Bio-Techne Corporation, Certara, Inc., Cryoport, Inc. and Guardant Health, Inc., among others. The Fiscal Years 2025-2027 LTIP Relative TSR peers names Cytek Biosciences, Inc., Evotec SE, Fulgent Genetics, Inc., MesaLabs, Inc. and Neogen Corporation, among others.
What is Azenta's chief executive pay ratio?
The company reported a chief executive pay ratio of 178.8:1 for fiscal 2025, against median employee compensation of $57,992.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stephen Schwartz
President and Chief Executive Officer
◇—◇—◇—◇◇
Matthew McManus
Former Executive Vice President and Chief Operating Officer
Departed during or after this year
◇◇◇—◇—◇◇
Lindon Robertson
Executive Vice President and Chief Financial Officer
◇◇◇—◇—◇◇
Jason Joseph
Senior Vice President, General Counsel/Corporate Secretary
◇◇◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stephen Schwartz
President and Chief Executive Officer
◇—◇—◇—◇◇
Lindon Robertson
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—◇—◇—◇◇
Jason Joseph
Senior Vice President, General Counsel & Corporate Secretary
◇—◇—◇—◇◇
Robin Vacha
Senior Vice President, Global Operations
◇—◇—◇—◇◇
David Gray
Senior Vice President, Chief Strategy and New Business Officer
◇—◇—◇—◇◇
Ginger Zhou
Senior Vice President, President GENEWIZ
◇—◇—◇—◇◇
Olga Pirogova
Senior Vice President and Chief Human Resources Officer
◇——————◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stephen Schwartz
Former President and Chief Executive Officer
Departed during or after this year
◇—◇—◇—◇◇
Herman Cueto
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇◇◇—◇—◇◇
Jason Joseph
Senior Vice President, General Counsel and Corporate Secretary
◇—◇—◇—◇◇
Ginger Zhou
Senior Vice President & General Manager Multiomics
◇—◇—◇—◇◇
David Wang
Senior Vice President & General Manager Sample Management Solutions
◇—◇—◇—◇◇
Olga Pirogova
Senior Vice President and Chief Human Resources Officer
◇—◇—◇—◇◇
John Marotta
President and Chief Executive Officer
◇—◇————◇
Lindon Robertson
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇———◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Marotta
President and Chief Executive Officer
◇—◇—◇—◇◇
Lawrence Lin
Executive Vice President and Chief Financial Officer
◇◇◇—◇—◇◇
Ephraim Starr
Senior Vice President, General Counsel and Corporate Secretary
◇—◇—◇—◇◇
Jason Joseph
Former Senior Vice President, General Counsel and Corporate Secretary
Departed during or after this year
◇—◇—◇—◇◇
Olga Pirogova
Senior Vice President and Chief Human Resources Officer
◇—◇—◇—◇◇
Ginger Zhou
Senior Vice President, President GENEWIZ
◇—◇—◇—◇◇
Herman Cueto
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇◇————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Ephraim StarrRSU◇——◇——◇
Ephraim StarrPSU◇◇◇—◇—◇
Ginger ZhouPSU◇◇◇—◇—◇
Ginger ZhouRSU◇——◇——◇
Jason W. JosephPSU◇◇◇—◇—◇
Jason W. JosephRSU◇——◇——◇
John MarottaPSU◇◇◇—◇—◇
John MarottaRSU◇——◇——◇
Lawrence LinRSU◇——◇——◇
Lawrence LinPSU◇◇◇—◇—◇
Lawrence LinRSU◇——◇——◇
Olga PirogovaPSU◇◇◇—◇—◇
Olga PirogovaRSU◇——◇——◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Lawrence LinPSU◇◇——
RSU◇◇——
John MarottaPSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Ephraim StarrPSU◇◇——
RSU◇◇——
Jason JosephPSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Ginger ZhouRSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Olga PirogovaPSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Ephraim Starr
Senior Vice President, General Counsel and Corporate Secretary · Amended agreement
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Ginger Zhou
Senior Vice President, President GENEWIZ · Consulting agreement
Equity acceleration on change in control◇
Excise tax treatment◇
Clawback◇
Herman Cueto
Former Executive Vice President and Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Benefits continuation◇
Excise tax treatment◇
Jason Joseph
Former Senior Vice President, General Counsel and Corporate Secretary · Terms as described in the company’s compensation discussion · citing a 2025 filing
Excise tax treatment◇
John Marotta
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Lawrence Lin
Executive Vice President and Chief Financial Officer · Amended agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Olga Pirogova
Senior Vice President and Chief Human Resources Officer · Amended agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Frank E. Casal
Board chair
◇◇————◇
Robyn C. Davis
◇◇————◇
Erica J. McLaughlin
◇◇————◇
Martin Madaus
◇◇————◇
Tina S. Nova
◇◇————◇
Tina Nova
◇◇————◇
Quentin G. Koffey
◇◇————◇
William L. Cornog
◇◇————◇
Alan Malus
◇◇————◇
Dipal Doshi
◇◇————◇
John P. Marotta served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics, Inc. TXG
  • Bio-Techne Corporation TECH
  • Certara, Inc. CERT
  • Cryoport, Inc. CYRX
  • Cytek Biosciences, Inc. CTKB
  • Evotec SE symbol not shown
  • Fulgent Genetics, Inc. FLGT
  • Guardant Health, Inc. GH
  • Haemonetics Corporation HAE
  • Maravai LifeSciences Holdings Inc. MRVI
  • Medpace Holdings, Inc. MEDP
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • Neogen Corporation NEOG
  • NeoGenomics, Inc. NEO
  • Repligen Corporation RGEN
  • Sotera Health Company SHC
  • Tandem Diabetes Care, Inc. TNDM
  • Twist Bioscience Corporation TWST
  • Veracyte, Inc. VCYT
Azenta Compensation Peer Group
  • 10x Genomics, Inc. TXG
  • Bio-Techne Corporation TECH
  • Certara, Inc. CERT
  • Cryoport, Inc. CPO
  • Guardant Health, Inc. GH
  • Haemonetics Corporation HAE
  • Maravai LifeSciences Holdings Inc. MRVI
  • Medpace Holdings, Inc. MEDP
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • NeoGenomics, Inc. NGM
  • Repligen Corporation RGEN
  • Sotera Health Company SOTR
  • Tandem Diabetes Care, Inc. TNDM
  • Twist Bioscience Corporation TWST
Fiscal Years 2025-2027 LTIP Relative TSR peers
  • Cytek Biosciences, Inc. CYTX
  • Evotec SE EVT
  • Fulgent Genetics, Inc. FLGT
  • MesaLabs, Inc. MESO
  • Neogen Corporation NEO
  • Veracyte, Inc. VZCY

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025January 28, 2026=◇◇◇
2024January 30, 2025=◇◇◇
2023January 30, 2024=◇◇◇
2022January 31, 2023=◇◇◇
2021January 24, 2022=◇◇◇
2020January 26, 2021=◇◇◇
2019January 24, 2020=◇◇◇
2018January 30, 2019=◇◇◇
2017January 31, 2018=◇◇◇
2016February 8, 2017=◇◇◇
2015January 27, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- John Marotta (President and Chief Executive Officer), FY2025 total compensation $10,371,414 (base salary $900,000) [exec_comp, SEC accession 0001140361-25-046064, filed 2025-12-18]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Azenta files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Azenta disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Azenta sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Azenta's disclosed peer group is defensible, who names Azenta back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
345 figures on this page: 334 cited to the filing that reported them, 11 calculated from figures it prints.
334 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001437749-26-011542
    Employment Agreement
  2. 0001437749-26-002409
    7,119,086 2,380,543 2. Approval, by a non-binding advisory vote, of the overall compensation of the Company’s named executive officers For Against Abstain Broker Non-Votes
  3. 0001140361-25-046158
    Director Compensation Table · Outstanding Equity Awards at Fiscal Year End Table · Summary Compensation Table
  4. 0001140361-25-046064
    Compensation Discussion and Analysis · Grants of Plan Based Awards Table · Summary Compensation Table
  5. 0001437749-25-002824
    8 509,126 2,108,951 2. Approval, by a non-binding advisory vote, of the overall compensation of the Company’s named executive officers For Against Abstain Broker Non-Votes
  6. 0001140361-24-049734
    Summary Compensation Table
  7. 0001558370-24-000691
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001140361-23-057904
    Summary Compensation Table
  9. 0001558370-23-000778
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001140361-22-046510
    Summary Compensation Table
  11. 0001558370-22-000586
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0000933974-21-000002
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0000933974-20-000002
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0000933974-19-000008
    Item 5.07 Submission of Matters to a Vote of Security Holders
  15. 0000933974-18-000004
    Item 5.07 Submission of Matters to a Vote of Security Holders
  16. 0000933974-17-000008
    Item 5.07 Submission of Matters to a Vote of Security Holders
  17. 0000933974-16-000055
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Azenta executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AZTA (accessed 2026).
Short form: data: Velarion

The Azenta brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
17 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Azenta and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Tech — Hardware rankings

Chief executive pay — Tech — HardwareCEO pay ratio — Tech — HardwareSay-on-pay support — Tech — Hardware

Peers Azenta discloses

The companies named in AZTA's own disclosed peer group.

10x Genomics, Inc.Bio-Techne CorporationCertara, Inc.Cryoport, Inc.Cytek Biosciences, Inc.Fulgent Genetics, Inc.Guardant Health, Inc.Haemonetics CorporationMaravai LifeSciences Holdings Inc.Medpace Holdings, Inc.Myriad Genetics, Inc.Natera, Inc.Neogen CorporationNeoGenomics, Inc.Repligen CorporationSotera Health CompanyTandem Diabetes Care, Inc.Twist Bioscience CorporationVeracyte, Inc.NeoGenomics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy